Vivos Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Vivos Therapeutics

30/03/2023 22:28

* Vivos Therapeutics Inc  VVOS.OQ  reported a quarterly
adjusted
loss of 20 cents​​ per share for the quarter ended in December.
The mean expectation of two analysts for the quarter was for a
loss of 22 cents per share.
    * Revenue fell 10.1% to $3.95 million from a year ago;
analysts
expected $4.55 million. 
    * Vivos Therapeutics Inc's reported EPS for the quarter was
a loss
of 20 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Vivos Therapeutics Inc shares had fallen by 17.8% this
quarter.
    * The company reported a quarterly loss of $6.09 million.
    * Wall Street's median 12-month price target for Vivos
Therapeutics Inc is $2.38 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 30 at 09:28 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.22          -0.20          Beat
 Jun. 30 2022      -0.28          -0.33          Missed
 Mar. 31 2022      -0.26          -0.26          Met